Prime Medicine, Inc. Files 2023 Annual Report on Form 10-K

Ticker: PRME · Form: 10-K · Filed: Mar 1, 2024 · CIK: 1894562

Prime Medicine, Inc. 10-K Filing Summary
FieldDetail
CompanyPrime Medicine, Inc. (PRME)
Form Type10-K
Filed DateMar 1, 2024
Risk Levelmedium
Pages15
Reading Time18 min
Key Dollar Amounts$0.00001, $15 million
Sentimentneutral

Sentiment: neutral

Topics: 10-K, Prime Medicine, Gene Editing, Biotechnology, SEC Filing

TL;DR

<b>Prime Medicine, Inc. has filed its 2023 10-K report detailing its operations and recent financing activities.</b>

AI Summary

Prime Medicine, Inc. (PRME) filed a Annual Report (10-K) with the SEC on March 1, 2024. Prime Medicine, Inc. filed its annual report on Form 10-K for the fiscal year ended December 31, 2023. The company is incorporated in Delaware and its principal executive offices are located at 21 Erie St., Cambridge, MA. Prime Medicine operates in the Biological Products (No Diagnostic Substances) industry, SIC code 2836. The filing covers the fiscal year from January 1, 2023, to December 31, 2023. Subsequent events include a public offering and warrant purchase agreement in February 2024.

Why It Matters

For investors and stakeholders tracking Prime Medicine, Inc., this filing contains several important signals. This 10-K filing provides a comprehensive overview of Prime Medicine's financial health, operational status, and strategic direction for the fiscal year 2023. The disclosure of subsequent events, including a February 2024 public offering and warrant agreement, offers insight into the company's recent capital-raising efforts and investor confidence.

Risk Assessment

Risk Level: medium — Prime Medicine, Inc. shows moderate risk based on this filing. The company is in the early stages of development for its gene editing therapies, which carry inherent scientific and regulatory risks, as detailed in the risk factors section of the 10-K.

Analyst Insight

Investors should review the detailed risk factors and financial statements in the 10-K to assess the company's long-term viability and potential for growth in the competitive gene editing market.

Key Numbers

  • 2023-12-31 — Fiscal Year End (Reporting period)
  • 2024-03-01 — Filing Date (Date of submission)
  • 001-41536 — SEC File Number (Company's SEC registration number)
  • 24707034 — Film Number (SEC processing number)

Key Players & Entities

  • Prime Medicine, Inc. (company) — Filer name
  • 21 Erie St., Cambridge, MA (location) — Business and mailing address
  • 2836 (industry_code) — Standard Industrial Classification
  • 2023-12-31 (date) — Fiscal year end
  • 2024-03-01 (date) — Filing date
  • February 2024 (date) — Subsequent event period

FAQ

When did Prime Medicine, Inc. file this 10-K?

Prime Medicine, Inc. filed this Annual Report (10-K) with the SEC on March 1, 2024.

What is a 10-K filing?

A 10-K is a comprehensive annual financial report required by the SEC, covering audited financials, business operations, risk factors, and management discussion. This particular 10-K was filed by Prime Medicine, Inc. (PRME).

Where can I read the original 10-K filing from Prime Medicine, Inc.?

You can access the original filing directly on the SEC's EDGAR system. The filing is publicly available and includes all exhibits and attachments submitted by Prime Medicine, Inc..

What are the key takeaways from Prime Medicine, Inc.'s 10-K?

Prime Medicine, Inc. filed this 10-K on March 1, 2024. Key takeaways: Prime Medicine, Inc. filed its annual report on Form 10-K for the fiscal year ended December 31, 2023.. The company is incorporated in Delaware and its principal executive offices are located at 21 Erie St., Cambridge, MA.. Prime Medicine operates in the Biological Products (No Diagnostic Substances) industry, SIC code 2836..

Is Prime Medicine, Inc. a risky investment based on this filing?

Based on this 10-K, Prime Medicine, Inc. presents a moderate-risk profile. The company is in the early stages of development for its gene editing therapies, which carry inherent scientific and regulatory risks, as detailed in the risk factors section of the 10-K.

What should investors do after reading Prime Medicine, Inc.'s 10-K?

Investors should review the detailed risk factors and financial statements in the 10-K to assess the company's long-term viability and potential for growth in the competitive gene editing market. The overall sentiment from this filing is neutral.

How does Prime Medicine, Inc. compare to its industry peers?

Prime Medicine operates in the biotechnology sector, focusing on gene editing therapies. This industry is characterized by high research and development costs, significant regulatory hurdles, and long development timelines.

Are there regulatory concerns for Prime Medicine, Inc.?

As a biotechnology company, Prime Medicine is subject to stringent regulations from bodies like the FDA concerning the development, testing, and approval of its therapeutic products. Compliance with these regulations is critical for market access.

Industry Context

Prime Medicine operates in the biotechnology sector, focusing on gene editing therapies. This industry is characterized by high research and development costs, significant regulatory hurdles, and long development timelines.

Regulatory Implications

As a biotechnology company, Prime Medicine is subject to stringent regulations from bodies like the FDA concerning the development, testing, and approval of its therapeutic products. Compliance with these regulations is critical for market access.

What Investors Should Do

  1. Analyze the financial statements within the 10-K to understand the company's cash burn rate and funding runway.
  2. Review the 'Risk Factors' section for potential challenges in clinical development, regulatory approval, and market adoption of their gene editing technologies.
  3. Investigate the details of the February 2024 public offering and warrant agreement to assess its impact on share dilution and future capital structure.

Key Dates

  • 2023-12-31: Fiscal Year End — End of the reporting period for the 10-K.
  • 2024-03-01: Filing Date — Date the 10-K was officially filed with the SEC.
  • 2024-02-29: Subsequent Event (Public Offering/Warrant Agreement) — Indicates recent financing activities post-fiscal year end.

Year-Over-Year Comparison

This is the initial 10-K filing for Prime Medicine, Inc. as a public company, providing a baseline for future financial and operational comparisons.

Filing Stats: 4,475 words · 18 min read · ~15 pages · Grade level 16.5 · Accepted 2024-03-01 08:04:30

Key Financial Figures

  • $0.00001 — ch Registered Common stock, par value $0.00001 per share PRME Nasdaq Global Market S
  • $15 million — ed to provide Prime Medicine with up to $15 million to support development of hotspot editi

Filing Documents

Risk Factors

Item 1A. Risk Factors 59

Unresolved Staff Comments

Item 1B. Unresolved Staff Comments 122 Item 1C. C ybersecurity 122

Properties

Item 2. Properties 123

Legal Proceedings

Item 3. Legal Proceedings 124

Mine Safety Disclosures

Item 4. Mine Safety Disclosures 124 PART II

Market for Registrant's Common Equity, Related Stockholder Matters and Issuer Purchases of Equity Securities

Item 5. Market for Registrant's Common Equity, Related Stockholder Matters and Issuer Purchases of Equity Securities 125

[Reserved]

Item 6. [Reserved] 125

Management's Discussion and Analysis of Financial Condition and Results of Operations

Item 7. Management's Discussion and Analysis of Financial Condition and Results of Operations 126

Quantitative and Qualitative Disclosures about Market Risk

Item 7A. Quantitative and Qualitative Disclosures about Market Risk 133

Financial Statements and Supplementary Data

Item 8. Financial Statements and Supplementary Data 134

Changes in and Disagreements with Accountants on Accounting and Financial Disclosure

Item 9. Changes in and Disagreements with Accountants on Accounting and Financial Disclosure 134

Controls and Procedures

Item 9A. Controls and Procedures 134

Other Information

Item 9B. Other Information 135

Disclosure Regarding Foreign Jurisdictions that Prevent Inspections

Item 9C. Disclosure Regarding Foreign Jurisdictions that Prevent Inspections 135 PART III

Directors, Executive Officers and Corporate Governance

Item 10. Directors, Executive Officers and Corporate Governance 136

Executive Compensation

Item 11. Executive Compensation 136

Security Ownership of Certain Beneficial Owners and Management and Related Stockholder Matters

Item 12. Security Ownership of Certain Beneficial Owners and Management and Related Stockholder Matters 136

Certain Relationships and Related Transactions, and Director Independence

Item 13. Certain Relationships and Related Transactions, and Director Independence 136

Principal Accountant Fees and Services

Item 14. Principal Accountant Fees and Services 136 PART IV

Exhibits and Financial Statement Schedules

Item 15. Exhibits and Financial Statement Schedules 137

Form 10-K Summary

Item 16. Form 10-K Summary 139 i References to Prime Medicine Throughout this Annual Report on Form 10-K, "Prime Medicine," "the Company," "we," "us," and "our," and similar expressions, except where the context requires otherwise, refer to Prime Medicine, Inc. and its consolidated subsidiaries, and "our board of directors" refers to the board of directors of Prime Medicine, Inc. From time to time we may use our website, our Twitter account (@PrimeMedicine) or our LinkedIn profile at https://www.linkedin.com/company/prime-medicine to distribute material information. Our financial and other material information is routinely posted to and accessible on the Investors section of our website, available at www.primemedicine.com. Investors are encouraged to review the Investors section of our website because we may post material information on that site that is not otherwise disseminated by us. Information that is contained in and can be accessed through our website or our social media is not incorporated into, and does not form a part of, this Annual Report on Form 10-K.We intend to apply for various trademarks that we use in connection with the operation of our business. This Annual Report on Form 10-K may also contain trademarks, service marks and trade names of third parties, which are the property of their respective owners. Our use or display of third parties' trademarks, service marks, trade names or products in this Annual Report on Form 10-K is not intended to, and does not imply a relationship with, or endorsement or sponsorship by us. Solely for convenience, the trademarks, service marks and trade names referred to in this Annual Report on Form 10-K may appear without the , SM and symbols, but the omission of such references is not intended to indicate, in any way, that we will not assert, to the fullest extent under applicable law, our rights or the right of the applicable owner of these trademarks, service marks and trade names. ii Cautionary Note Re

Business

ITEM 1. Business Overview We are a biotechnology company committed to delivering a new class of differentiated one-time curative genetic therapies to address the widest spectrum of diseases. We are deploying Prime Editing technology, which we believe is a versatile, precise, and efficient gene editing technology. In the past forty years, the genetic disorders causing many diseases have become more clear. Genetic mutations implicated in disease are diverse and can range from a single base error, which are known as point mutations, to errors that extend from two bases to several to thousands of bases, including multi-base insertions, deletions, duplications, or combinations thereof. Some mutations affect the coding regions of genes while others affect regulatory sequences that control the function of genes and can affect the function of larger biochemical and genetic pathways. Furthermore, as revealed by population-level genomic studies, natural genetic variations are known to protect against or to increase risk of disease. Given these insights, we believe that gene editing has the potential to treat and even cure many human diseases. The field of genetic medicine has evolved tremendously over the last decade, with groundbreaking advances in gene therapy, cell therapy, ribonucleic acid, or RNA, therapy, and, more recently, gene editing. This past year saw the first CRISPR/Cas9-based gene editing therapy (CASGEVY) approval by the U.S. Food and Drug Administration, or the FDA, for the treatment of sickle cell disease. These technologies represent significant advancements for genetic therapies but we believe Prime Editing is the only gene editing technology that, by itself, can edit, correct, insert and delete deoxyribonucleic acid, or DNA, sequences in any target tissue. We believe Prime Editing technology has transformative potential that could change the course of how many diseases is treated and overcome the challenges associated with current genetic therapies.

View Full Filing

View this 10-K filing on SEC EDGAR

View on ReadTheFiling | About | Contact | Privacy | Terms

Data from SEC EDGAR. Not affiliated with the SEC. Not investment advice. © 2026 OpenDataHQ.